<DOC>
	<DOCNO>NCT01111240</DOCNO>
	<brief_summary>This study documentation effectiveness safety Humira patient psoriatic arthritis .</brief_summary>
	<brief_title>Efficacy Safety HumiraÂ® Patients With Psoriatic Arthritis Normal Medical Practice</brief_title>
	<detailed_description>Psoriatic Arthritis participant receive adalimumab evaluate prospective , non-interventional study ( NIS ) 2 year . Patients receive adalimumab 40 mg every week ( eow ) , per label . Efficacy safety parameter measure routinely baseline 3 , 6 , 9 , 12 , 18 24 month .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inclusion : 18 year age old ( young patient may enrol discretion physician ) Diagnosis Psoriatic Arthritis ( indication discretion physician ) initiate adalimumab therapy Signed/dated Informed Consent Exclusion :</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Humira</keyword>
	<keyword>Long-term safety effectiveness</keyword>
	<keyword>Psoriatic Arthritis</keyword>
</DOC>